PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
65.60%
Revenue growth of 65.60% vs. zero growth in Drug Manufacturers - Specialty & Generic. Walter Schloss might still want to see if it can translate into profits.
109.55%
Gross profit growth of 109.55% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that could be built upon.
77.73%
Positive EBIT growth while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch might see a strong competitive advantage in operations.
77.73%
Positive operating income growth while Drug Manufacturers - Specialty & Generic is negative. Peter Lynch would spot a big relative advantage here.
115.00%
Positive net income growth while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch would view this as a notable competitive advantage.
115.13%
EPS growth of 115.13% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
114.87%
Diluted EPS growth of 114.87% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could improve over time.
0.41%
Share change of 0.41% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if the modest difference matters long-term.
1.04%
Diluted share change of 1.04% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
14.93%
OCF growth of 14.93% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss might see a modest positive difference, which can compound over time.
21.35%
FCF growth of 21.35% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1088.27%
3Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 6.46%. Joel Greenblatt might see a short-term competitive advantage at play.
-5491.93%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-3771.73%
Negative 5Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-1815.90%
Negative 3Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
1243.82%
Net income/share CAGR of 1243.82% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
413.21%
5Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 4.87%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
272.91%
3Y net income/share CAGR of 272.91% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a small advantage that can be scaled further.
5974.97%
Equity/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 62.52% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
13212.67%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 38.02%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
1278.80%
3Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 20.77%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
27.87%
AR growth of 27.87% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
3.14%
Inventory growth of 3.14% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
15.58%
Asset growth of 15.58% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
-2.05%
Negative BV/share change while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
513.53%
Debt growth of 513.53% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
14.17%
R&D growth of 14.17% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
-22.82%
SG&A decline while Drug Manufacturers - Specialty & Generic grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.